TCTR20140823001已完成未知
Pharmacist with telephone intervention in diabetes patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 315
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •type 2 diabetes mellitus and HbA1C more than 7
排除标准
- •pregnancy and lactation
研究者
相似试验
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)EUCTR2018-001508-12-FRovartis Pharma AG120
已完成
2 期
A study to assess safety and preliminary clinical efficacy of VAY736 and CFZ533 in patients with systemic lupus erythematosussystemic lupus erythematosusJPRN-jRCT2080224123ovartis Pharma K.K.120
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)EUCTR2018-001508-12-CZovartis Pharma AG135
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)MedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-001508-12-DEovartis Pharma AG135
进行中（未招募）
1 期
Study the efficacy and safety of VAY736 and CFZ533 in patients with systemic lupus erythematosus (SLE)EUCTR2018-001508-12-ESovartis Farmacéutica, S.A.120